🚀 go-pugleaf

Cancer – Press Review  – Revue de Presse

Every week on http://marclacroixcancerblog.blogspot.com
Chaque semaine sur http://marclacroixcancerblog.blogspot.com




Press review  (September 10, 2011) – Revue de presse (10 septembre
2011)


Annual Breast Exams, Mammograms Still Key to Detecting Breast Cancer
Third of tumors were spotted in a breast exam by a doctor or a self-
exam, study finds.
By Amanda Gardner. In U.S. News & World Report
http://health.usnews.com/health-news/family-health/cancer/articles/2011/09/07/annual-breast-exams-mammograms-still-key-to-detecting-breast-cancer

Zytiga® Approved in the European Union for Metastatic Castration-
Resistant Prostate Cancer
Janssen-Cilag International NV announced today that, after an
accelerated regulatory review process by the European Medicines Agency
(EMA) and following a positive CHMP opinion on the 22 July 2011, the
European Commission has approved the marketing authorisation for
ZYTIGA® (abiraterone acetate), a novel, once-daily, oral, androgen
biosynthesis inhibitor. Abiraterone acetate is approved, in
combination with prednisone or prednisolone, for the treatment of
metastatic castration-resistant prostate cancer (mCRPC) in adult men
whose disease has progressed on or after a docetaxel-based
chemotherapy regimen.
PR Newswire UK (press release)
http://www.prnewswire.co.uk/cgi/news/release?id=331987

Worldwide cancer rates 'could be cut by 2.8m with healthier lifestyles
and diets'
World Cancer Research Fund study says disease can be widely prevented
as UN prepares to hold summit to tackle soaring rates. By Sarah
Boseley. In The Guardian
http://www.guardian.co.uk/world/2011/sep/07/worldwide-cancer-rates-healthier-lifestyles

NICE changes mind to back Takeda bone cancer drug
Britain's health costs watchdog NICE has decided to back Japanese
group Takeda's bone cancer drug Mepact after re-assessing the impact
of a discount on the medicine for patients in the state-funded
National Health Service (NHS).
By Kate Kelland, Dan Lalor. Reuters
http://www.reuters.com/article/2011/09/07/takeda-mepact-nice-idUSL5E7K72K020110907

Beat enzyme, curb cancer: study
Scientists from the Genome Institute of Singapore (GIS), an institute
of the Agency for Science, Technology and Research (A*STAR), and their
colleagues at the National University of Singapore (NUS), have
uncovered a new way to target EZH2, an enzyme that promotes the
estrogen receptor-negative breast cancer, a type of breast cancer that
is aggressive and unresponsive to current forms of treatment.
In ScienceAlert
http://www.sciencealert.com.au/news/20110709-22580.html

UK NICE Rejects 3 Drugs for Metastatic Colorectal Cancer‎
Three targeted therapies — bevacizumab (Avastin), cetuximab (Erbitux),
and panitumumab (Vectibix, Amgen) — have been rejected in the United
Kingdom for use in patients with metastatic colorectal cancer that has
progressed after first-line therapy. By Zosia Chustecka. In Medscape
http://www.medscape.com/viewarticle/749150

Cancer Research UK opens olaparib and temozolomide Phase I combination
trial in glioblastoma
Cancer Research UK's Drug Development Office has opened a trial of a
new combination of drugs for the treatment of patients with brain
cancer.
In News-Medical.net
http://www.news-medical.net/news/20110907/Cancer-Research-UK-opens-olaparib-and-temozolomide-Phase-I-combination-trial-in-glioblastoma.aspx

TNF Treatment for Rheumatoid Arthritis Boosts Skin Cancer Risk‎‎
But review also finds the drugs don't heighten risks for other
cancers.
In U.S. News & World Report
http://health.usnews.com/health-news/family-health/cancer/articles/2011/09/08/tnf-treatment-for-rheumatoid-arthritis-boosts-skin-cancer-risk

Bisphosphonate Cancer Risk Divides FDA Officials‎‎
Food and Drug Administration officials disagree over whether the long-
term use of oral bisphosphonates increases the risk of esophageal
cancer, background documents released before an advisory committee
meeting show. By Martin Berman-Gorvine. In The Oncology Report
http://www.oncologyreport.com/news/clinical/single-article/bisphosphonate-cancer-risk-divides-fda-officials/1a89e68204.html

Novel Approach Scores First Success Against Elusive Cancer Gene
Dana-Farber Cancer Institute scientists have successfully disrupted
the function of a cancer gene involved in the formation of most human
tumors by tampering with the gene's "on" switch and growth signals,
rather than targeting the gene itself. The results, achieved in
multiple myeloma cells, offer a promising strategy for treating not
only myeloma but also many other cancer types driven by the gene MYC,
the study authors say. Their findings are being published by the
journal Cell on its website Sept. 1 and in its Sept. 16 print edition.
In Newswise
http://www.newswise.com/articles/novel-approach-scores-first-success-against-elusive-cancer-gene

Cancers du sein : découverte d'un marqueur de risque de métastases
pulmonaires‎
Des chercheurs français ont identifié un marqueur du risque de
développer des métastases pulmonaires chez les femmes atteintes de
cancers du sein, selon des travaux publiés mardi. En agissant sur ce
marqueur, dénommé "Kindlin-1", les chercheurs espèrent pouvoir bloquer
la prolifération des cellules tumorales et ainsi contenir le pouvoir
agressif des tumeurs à fort risque de dissémination pulmonaire. AFP
http://www.google.com/hostednews/afp/article/ALeqM5hh6dgG5Rg9l0ACWmHJVcunVqBZGg?docId=CNG.038c9b84735f21154008f7815ea7dbc8.2e1

Novartis: feu vert de Bruxelles pour l'Afinitor
Novartis a reçu l'approbation de la Commission européenne pour la
commercialisation de son médicament Afinitor dans le traitement de
patients atteints de tumeurs neuro-endocrines du pancréas à un stade
avancé.
Dans L’Express
http://votreargent.lexpress.fr/bourse/fiches-valeurs/novartis-feu-vert-de-bruxelles-pour-l-afinitor-depeche_165021.html

Un médicament désormais contre-indiqué chez les enfants cancéreux.
Un médicament utilisé en cancérologie, le Cardioxane des laboratoires
Novartis, est désormais contre-indiqué chez les enfants et les
adolescents en raison d'un risque accru de cancers secondaires à ce
traitement, selon l'Agence française de sécurité sanitaire des
produits de santé (Afssaps).
AFP
http://www.google.com/hostednews/afp/article/ALeqM5io5_XDVdGqk09UWNb8oBDcdRjcgA?docId=CNG.e3e62b390cffc5423c2c1377a8fa0e88.a1

Tchernobyl : quelles conséquences pour la France ?‎
Les données dont on dispose sur les retombées du nuage de Tchernobyl
sur la France sont éparses et interprétées de diverses façons. Une
chose est sûre, l'augmentation des cancers de la thyroïde avait
commencé bien avant 1986.
Par André Aurengo. Dans Pour la Science
http://www.pourlascience.fr/ewb_pages/f/fiche-article-tchernobyl-quelles-consequences-pour-la-france-19619.php

Travailler debout, ça vous tente?
Alors que certains salariés prônent la sieste en entreprise, d'autres
militent pour travailler debout. D'après une étude de l'American
Cancer Society, rester assis plus de six heures par jour accroitrait
de 37% le risque de mort prématurée chez les femmes.  Par Elodie
Bousquet. Dans L’Express
http://www.lexpress.fr/emploi-carriere/emploi/travailler-debout-ca-vous-tente_1028223.html











Cancer Blog – Marc Lacroix – Le Blogue du Cancer
http://marclacroixcancerblog.blogspot.com










Marc Lacroix – InTextoResearch – Baelen  (09/2011)